| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/06/2006 | US7056909 5,5-Difluoro-3(S)-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-(1, 8)-naphthyridin-2-yl)-nonanoic acid; inhibition of bone resorption, restenosis, angiogenesis, retinopathy, macular degeneration, arthritis, metastatic tumor growth, etc. |
| 06/06/2006 | US7056908 Containing indolecarbazole compounds, such as staurosporine. |
| 06/06/2006 | US7056904 Therapy for bone disorders; osteoporosis; vitamin deficiency |
| 06/06/2006 | US7056902 4-dedimethylamino tetracycline compounds |
| 06/06/2006 | US7056895 1-(3,4-dihydroxy-5-methylol-tetrahydrofur-2-yl),3-amidino-1H-1,2,4- triazoles; infections, infestations, autoimmune diseases; anticarcinogenic and -tumor agents; HIV, hepatitis C, human papilloma virus and giant cell arteritis |
| 06/06/2006 | US7056885 Fibroblast growth factor and nucleic acids encoding same |
| 06/06/2006 | US7056884 Reduced FK228 and use thereof |
| 06/06/2006 | US7056883 Therapeutic agent for soft tissue sarcoma |
| 06/06/2006 | US7056719 Polypeptide-phosphatidic acid phosphatase 29.81 and the polynucleotide encoding said polypeptide |
| 06/06/2006 | US7056704 RNA interference mediating small RNA molecules |
| 06/06/2006 | US7056692 Modulation of pleiotrophin signaling by receptor-type protein tyrosine phosphatase beta/zeta |
| 06/06/2006 | US7056689 Methods of treating and detecting cancer using viruses |
| 06/06/2006 | US7056514 Partial peptide mimetics and methods |
| 06/06/2006 | US7056509 Monoclonal antibodies used as antagonists vascular endothelial growth factors (VEGF); angiogenesis inhibitors; antitumor agents |
| 06/06/2006 | US7056505 Antibody for use in the diagnosis, prevention and treatment of infections, autoimmune disorders, arthritis, graft rejection and graft-versus-host disease |
| 06/06/2006 | US7056275 Radiotherapy |
| 06/06/2006 | CA2457852C Multivesicular emulsion topical delivery systems |
| 06/06/2006 | CA2352592C Quinazolinone compounds |
| 06/06/2006 | CA2327723C Bicyclic hydroxamic acid derivatives |
| 06/06/2006 | CA2213810C Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods |
| 06/06/2006 | CA2145514C Process for the preparation of 9-amino camptothecin |
| 06/06/2006 | CA2136356C 1,2,3-triazole and imidazole compounds and their antitumor use |
| 06/06/2006 | CA2120153C Recombinant immunotoxins |
| 06/01/2006 | WO2006058121A1 Crystalline forms of 3'-tert-butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-n-debenzoyl-4-o-methoxycarbonyl-paclitaxel |
| 06/01/2006 | WO2006058077A1 Dap-10 and uses thereof |
| 06/01/2006 | WO2006058012A2 Gonadotropin releasing hormone receptor antagonists |
| 06/01/2006 | WO2006057998A1 Binary antitumor compositions platinum (iv) derivatives |
| 06/01/2006 | WO2006057932A2 2-METHYLENE-18,19-DINOR-1α-HYDROXY-HOMOPREGNACALCIFEROL AND ITS USES |
| 06/01/2006 | WO2006057902A2 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses |
| 06/01/2006 | WO2006057901A2 2-METHYLENE-19-NOR-1α-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES |
| 06/01/2006 | WO2006057900A2 17,20(z)-dehydro vitamin d analogs and their uses |
| 06/01/2006 | WO2006057899A2 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses |
| 06/01/2006 | WO2006057886A2 2-METHYLENE-19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND ITS USES |
| 06/01/2006 | WO2006057885A2 17,20(e)-dehydro vitamin d analogs and their uses |
| 06/01/2006 | WO2006057884A2 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES |
| 06/01/2006 | WO2006057289A1 Novel shuttle vector |
| 06/01/2006 | WO2006057270A1 Nitrogeneous tricyclic compound |
| 06/01/2006 | WO2006057217A1 Dfrp proteins regulating drg proteins and utilization of the same |
| 06/01/2006 | WO2006057154A1 Efficacy enhancing agent for anticancer drug |
| 06/01/2006 | WO2006056760A1 A combination of n-(3-metoxy-5-methylpyrazin-2-yl)-2-(4-`1,3,4-oxadiazol-2-yl!phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer |
| 06/01/2006 | WO2006056696A2 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof |
| 06/01/2006 | WO2006056449A1 Copper melphalan and copper tegafur used as anti-tumoral agents |
| 06/01/2006 | WO2006056427A1 Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders |
| 06/01/2006 | WO2006056399A2 Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| 06/01/2006 | WO2006056054A1 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| 06/01/2006 | WO2006037981A8 Inhibition of tumour cell migration |
| 06/01/2006 | WO2006031337A3 Combinations of pkc activators and pkc inhibitors for alzheimer’s disease treatment and cognitive enhancement |
| 06/01/2006 | WO2006029487A3 Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis |
| 06/01/2006 | WO2006029020A3 Treatments of refractory cancers using na+/k+-atpase inhibitors |
| 06/01/2006 | WO2006028523A3 Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
| 06/01/2006 | WO2006020720A3 Stable pegylated interferon formulation |
| 06/01/2006 | WO2006020403A3 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| 06/01/2006 | WO2006018185A8 Dihydropteridinones for the treatment of cancer diseases |
| 06/01/2006 | WO2006016067A3 Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer |
| 06/01/2006 | WO2006014706A3 Methotrexate derivatives useful for treating cancer and arthritis |
| 06/01/2006 | WO2006003068A3 Alpha-amino acid derivatives with antiinflammatory activity |
| 06/01/2006 | WO2005118071A3 Tetrahydropyridothiophenes |
| 06/01/2006 | WO2005107752A3 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
| 06/01/2006 | WO2005095399A3 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors |
| 06/01/2006 | WO2005037866A8 Igg3 anti rhesus-d in the line yb2/0 having a high phagocytosis activity |
| 06/01/2006 | WO2003025542A3 Immune response associated proteins |
| 06/01/2006 | US20060117414 Fad4, Fad5, Fad5-2, and Fad6, novel fatty acid desaturase family members and uses thereof |
| 06/01/2006 | US20060116516 2-[[4-[[[4-(Aminosulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-4-methyl-5-thiazolecarboxylic acid, ethyl ester; 4-Methyl-2-[[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-5-thiazolecarboxylic acid, ethyl ester; Antiinflammatory agents; rheumatic diseases |
| 06/01/2006 | US20060116388 CXCR3 antagonists |
| 06/01/2006 | US20060116381 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-ben-zamide for treating mutated-ret kinase associated diseases |
| 06/01/2006 | US20060116379 Compounds exhibiting type X sPLA2 inhibiting effect |
| 06/01/2006 | US20060116374 substituted bis/thiohydrazide amide compound; synergistic effect with taxol or taxotere, anticancer agents, side effect reduction |
| 06/01/2006 | US20060116364 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer |
| 06/01/2006 | US20060116346 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 06/01/2006 | US20060115879 Process for producing anticancer agent LL-D45042 |
| 06/01/2006 | US20060115813 Intracellular signaling molecules |
| 06/01/2006 | US20060115542 Therapeutic delivery of carbon monoxide |
| 06/01/2006 | US20060115480 Disease treatment via antimicrobial peptide inhibitors |
| 06/01/2006 | US20060115477 Neuropilin-1 inhibitors |
| 06/01/2006 | US20060115470 Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| 06/01/2006 | US20060115452 Uses of interleukin-18 for treating skin disorders associated with uv radiations |
| 06/01/2006 | US20060115451 Modified cytokines for use in cancer therapy |
| 06/01/2006 | US20060115424 Combination therapy of oxaliplatin and radioactively doped particles treating cancer |
| 06/01/2006 | DE102004057645A1 New substituted pteridine compounds, useful as phosphodiesterase 4 inhibitors for treating e.g. inflammatory diseases, cancer, asthma, ulcerative colitis, depression and schizophrenia |
| 06/01/2006 | DE102004057618A1 Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen Substituted pteridines for the treatment of inflammatory diseases |
| 06/01/2006 | DE102004057195A1 Kristalline Modifikationen von Crystalline modifications of N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon and / or salts thereof |
| 06/01/2006 | DE102004056727A1 Kupfer-Melphalan und Kupfer-Tegafur als Antitumormittel Copper and copper-melphalan tegafur as an antitumor agent |
| 06/01/2006 | CA2595305A1 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof |
| 06/01/2006 | CA2588434A1 Copper melphalan and copper tegafur used as anti-tumoral agents |
| 06/01/2006 | CA2588412A1 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses |
| 06/01/2006 | CA2588406A1 2-.alpha.-methyl and 2-.beta.-methyl analogs of 19,26,27-trinor-(20s-1.alpha.-hydroxyvitamin d3 and their uses |
| 06/01/2006 | CA2588401A1 17,20(z)-dehydro vitamin d analogs and their uses |
| 06/01/2006 | CA2588399A1 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses |
| 06/01/2006 | CA2588396A1 17,20(e)-dehydro vitamin d analogs and their uses |
| 06/01/2006 | CA2587853A1 Gonadotropin releasing hormone receptor antagonists |
| 06/01/2006 | CA2587572A1 Dap-10 and uses thereof |
| 06/01/2006 | CA2587178A1 Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders |
| 06/01/2006 | CA2587140A1 A combination of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer |
| 06/01/2006 | CA2586605A1 Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| 06/01/2006 | CA2586126A1 Novel shuttle vector |
| 06/01/2006 | CA2585990A1 Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof |
| 06/01/2006 | CA2584646A1 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| 06/01/2006 | CA2583315A1 Method and composition for enhancing anti-angiogenic therapy |
| 06/01/2006 | CA2579962A1 Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders |
| 06/01/2006 | CA2502479A1 Laminin receptor binding molecule |